June 24, 2021

Biosimilars are increasing the number of safe, effective treatments for cancer. How can policies ensure that they’re accessible for oncologists to personalize cancer care?

Read Paper

Tags: Biologics, Oncology

Categorized in: Policy Briefs, Policy Papers

Recent Blog Posts

Narrowing the Gout Information Gap May 20, 2022

Countering a Lack of Information and Loss of Hope for Gout Patients May 19, 2022

Pharmacists Poised to Play Larger Role in Uptake of Biosimilars May 13, 2022

Biosimilars: Expanding Options for Cancer Care

June 24, 2021

Recent Blog Posts